GLP-1 medications are generally safe but may cause: Common: Nausea, vomiting, digestive changes, fatigue Rare but serious: Pancreatitis Alcohol interaction: Semaglutide may alter alcohol metabolism, potentially increasing intoxication risk from smaller amounts of alcohol
Current expectations point to FDA review and potential approval in the 2027 to 2028 range
Stimulant-free, 31 servings per bottle
197,200 It is plausible that GLP-1 directly decreases appetite, as this would allow ingested nutrients to be digested and prevent hyperglycaemia/hyperlipidaemia or undesirable nutrient storage by more ingestion of nutrients
Based on these retrospective analyses, one could argue that all newly diagnosed, as well as established, type 2 diabetes patients should be started simultaneously, within a few weeks to months, on an SGLT2 inhibitor plus a GLP-1 receptor agonist
Treatments are carefully selected based on lab testing, symptoms, and health goals to ensure optimal effectiveness and safety
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
